Published in Blood on October 03, 2002
Dysregulated arginine metabolism, hemolysis-associated pulmonary hypertension, and mortality in sickle cell disease. JAMA (2005) 6.14
Diastolic dysfunction is an independent risk factor for death in patients with sickle cell disease. J Am Coll Cardiol (2007) 2.76
Hemodynamic and functional assessment of patients with sickle cell disease and pulmonary hypertension. Am J Respir Crit Care Med (2007) 2.68
Platelet activation in patients with sickle disease, hemolysis-associated pulmonary hypertension, and nitric oxide scavenging by cell-free hemoglobin. Blood (2007) 2.31
Hemolysis in sickle cell mice causes pulmonary hypertension due to global impairment in nitric oxide bioavailability. Blood (2007) 2.30
An official American Thoracic Society clinical practice guideline: diagnosis, risk stratification, and management of pulmonary hypertension of sickle cell disease. Am J Respir Crit Care Med (2014) 2.23
Left ventricular hypertrophy and diastolic dysfunction in children with sickle cell disease are related to asleep and waking oxygen desaturation. Blood (2010) 2.19
Vasculopathy in sickle cell disease: Biology, pathophysiology, genetics, translational medicine, and new research directions. Am J Hematol (2009) 2.05
Hemolysis-associated priapism in sickle cell disease. Blood (2005) 1.86
Pathogenic mechanisms of pulmonary arterial hypertension. J Mol Cell Cardiol (2007) 1.85
The relationship between the severity of hemolysis, clinical manifestations and risk of death in 415 patients with sickle cell anemia in the US and Europe. Haematologica (2012) 1.72
Hospitalization for pain in patients with sickle cell disease treated with sildenafil for elevated TRV and low exercise capacity. Blood (2011) 1.64
Sildenafil therapy in patients with sickle cell disease and pulmonary hypertension. Br J Haematol (2005) 1.47
Managing sickle cell disease. BMJ (2003) 1.43
Cardiomyopathy With Restrictive Physiology in Sickle Cell Disease. JACC Cardiovasc Imaging (2016) 1.42
Beyond the definitions of the phenotypic complications of sickle cell disease: an update on management. ScientificWorldJournal (2012) 1.40
Cardiopulmonary complications of sickle cell disease: role of nitric oxide and hemolytic anemia. Hematology Am Soc Hematol Educ Program (2005) 1.36
Pulmonary complications of sickle cell disease. Am J Respir Crit Care Med (2012) 1.35
The critical roles of platelet activation and reduced NO bioavailability in fatal pulmonary arterial hypertension in a murine hemolysis model. Blood (2010) 1.35
Hemolysis-associated pulmonary hypertension in thalassemia. Ann N Y Acad Sci (2005) 1.35
Relative systemic hypertension in patients with sickle cell disease is associated with risk of pulmonary hypertension and renal insufficiency. Am J Hematol (2008) 1.34
Severity of pulmonary hypertension during vaso-occlusive pain crisis and exercise in patients with sickle cell disease. Br J Haematol (2006) 1.34
Cardiovascular abnormalities in sickle cell disease. J Am Coll Cardiol (2012) 1.31
Amplified expression profiling of platelet transcriptome reveals changes in arginine metabolic pathways in patients with sickle cell disease. Circulation (2007) 1.29
Identification of genetic polymorphisms associated with risk for pulmonary hypertension in sickle cell disease. Blood (2008) 1.28
Cardiopulmonary complications leading to premature deaths in adult patients with sickle cell disease. Am J Hematol (2010) 1.28
Exercise capacity and haemodynamics in patients with sickle cell disease with pulmonary hypertension treated with bosentan: results of the ASSET studies. Br J Haematol (2010) 1.25
Prospective echocardiography assessment of pulmonary hypertension and its potential etiologies in children with sickle cell disease. Am J Cardiol (2009) 1.22
Pulmonary hypertension in sickle cell disease: relevance to children. Pediatr Hematol Oncol (2007) 1.21
Pleiotropic effects of intravascular haemolysis on vascular homeostasis. Br J Haematol (2009) 1.20
Proteomic identification of altered apolipoprotein patterns in pulmonary hypertension and vasculopathy of sickle cell disease. Blood (2008) 1.18
Pulmonary arterial hypertension. Orphanet J Rare Dis (2013) 1.18
Elevated tricuspid regurgitation velocity and decline in exercise capacity over 22 months of follow up in children and adolescents with sickle cell anemia. Haematologica (2010) 1.16
Hemodynamic predictors of mortality in adults with sickle cell disease. Am J Respir Crit Care Med (2013) 1.16
Mutations and polymorphisms in hemoglobin genes and the risk of pulmonary hypertension and death in sickle cell disease. Am J Hematol (2008) 1.15
Nitric oxide and arginine dysregulation: a novel pathway to pulmonary hypertension in hemolytic disorders. Curr Mol Med (2008) 1.07
Infrared imaging of nitric oxide-mediated blood flow in human sickle cell disease. Microvasc Res (2012) 1.06
Vasculopathy and pulmonary hypertension in sickle cell disease. Am J Physiol Lung Cell Mol Physiol (2014) 1.03
Pulmonary hypertension in hemolytic disorders: pulmonary vascular disease: the global perspective. Chest (2010) 1.03
Endothelin receptor antagonists for pulmonary hypertension in adult patients with sickle cell disease. Br J Haematol (2009) 1.03
Sildenafil in the treatment of pulmonary hypertension. Vasc Health Risk Manag (2006) 0.99
Sickle cell disease: new opportunities and challenges in Africa. ScientificWorldJournal (2013) 0.97
Severe painful vaso-occlusive crises and mortality in a contemporary adult sickle cell anemia cohort study. PLoS One (2013) 0.96
Mixed haematopoietic chimerism for sickle cell disease prevents intravascular haemolysis. Br J Haematol (2007) 0.96
Urinary albumin excretion is associated with pulmonary hypertension in sickle cell disease: potential role of soluble fms-like tyrosine kinase-1. Eur J Haematol (2010) 0.96
Pulmonary hypertension associated with chronic hemolytic anemia and other blood disorders. Clin Chest Med (2013) 0.95
Characterization of altered patterns of endothelial progenitor cells in sickle cell disease related pulmonary arterial hypertension. Pulm Circ (2012) 0.91
Medical management of ischemic stuttering priapism: a contemporary review of the literature. Asian J Androl (2011) 0.89
NT-proBNP as a marker of cardiopulmonary status in sickle cell anaemia in Africa. Br J Haematol (2010) 0.89
Right ventricular and pulmonary function in sickle cell disease patients with pulmonary hypertension. Pediatr Cardiol (2006) 0.88
Could uric acid be a modifiable risk factor in subjects with pulmonary hypertension? Med Hypotheses (2010) 0.84
Pulmonary hypertension associated with sickle cell disease: pathophysiology and rationale for treatment. Lung (2008) 0.84
Sickle cell anemia mice develop a unique cardiomyopathy with restrictive physiology. Proc Natl Acad Sci U S A (2016) 0.83
Clinical and electrocardiographic evaluation of sickle-cell anaemia patients with pulmonary hypertension. ISRN Hematol (2012) 0.83
Correlation of N-terminal fragment of B-type natriuretic peptide levels with clinical, laboratory, and echocardiographic abnormalities in children with sickle cell disease. J Pediatr (2011) 0.82
Prevalence of pulmonary hypertension in sickle cell anaemia patients of a tertiary hospital in Nigeria. Niger Med J (2014) 0.81
Pathophysiology and treatment of pulmonary hypertension in sickle cell disease. Blood (2016) 0.80
Pharmacological management of sickle cell disease. P T (2008) 0.79
TRV: a physiological biomarker in sickle cell disease. Pediatr Blood Cancer (2011) 0.78
Uric Acid as a potential biomarker of pulmonary arterial hypertension in patients with sickle cell disease. Indian J Hematol Blood Transfus (2011) 0.77
Echocardiographic evaluation of left ventricular diastolic and systolic function in Saudi patients with sickle cell disease. J Saudi Heart Assoc (2012) 0.77
The role of phosphodiesterase inhibitors in the management of pulmonary vascular diseases. Glob Cardiol Sci Pract (2014) 0.76
Dysregulation of ubiquitin-proteasome pathway and apolipoprotein A metabolism in sickle cell disease-related pulmonary arterial hypertension. Pulm Circ (2013) 0.76
Increased Red Blood Cell Stiffness Increases Pulmonary Vascular Resistance and Pulmonary Arterial Pressure. J Biomech Eng (2016) 0.76
Updated role of nitric oxide in disorders of erythrocyte function. Cardiovasc Hematol Disord Drug Targets (2013) 0.76
LimiTT: link miRNAs to targets. BMC Bioinformatics (2016) 0.75
Peroxisome Proliferator-Activated Receptor γ Regulates the V-Ets Avian Erythroblastosis Virus E26 Oncogene Homolog 1/microRNA-27a Axis to Reduce Endothelin-1 and Endothelial Dysfunction in the Sickle Cell Mouse Lung. Am J Respir Cell Mol Biol (2017) 0.75
Author's Reply. Pulm Circ (2013) 0.75
Pulmonary vascular and ventricular dysfunction in the susceptible patient (2015 Grover Conference series). Pulm Circ (2016) 0.75
Prevalence of pulmonary arterial hypertension among sickle cell disease patients in Al Hassa. Glob J Health Sci (2013) 0.75
Saudi Guidelines on the Diagnosis and Treatment of Pulmonary Hypertension: Pulmonary hypertension associated with hemolytic anemia. Ann Thorac Med (2014) 0.75
Is resistance futile?: Hemodynamics in sickle cell disease. Am J Respir Crit Care Med (2013) 0.75
Reversal of pre-capillary pulmonary hypertension in a patient with sickle cell anemia who underwent haploidentical peripheral blood stem cell transplantation. Bone Marrow Transplant (2017) 0.75
Group 5 Pulmonary Hypertension: The Orphan's Orphan Disease. Cardiol Clin (2016) 0.75
Pulmonary hypertension in Nigerian adults with sickle cell anemia. Vasc Health Risk Manag (2017) 0.75
Review: Hemodynamic Characteristics and Outcomes of Sickle Cell Disease Associated Pulmonary Hypertension. Ethn Dis (2016) 0.75
Living kidney donors ages 70 and older: recipient and donor outcomes. Clin J Am Soc Nephrol (2011) 1.45